Avillion LLP gets initial funding from Abingworth, Clarus Ventures

By Admin
Avillion LLP, which focuses on clinical co-development of therapeutics, has said it has secured initial funding from A...

Avillion LLP, which focuses on clinical co-development of therapeutics, has said it has secured initial funding from Abingworth LLP and Clarus Ventures. UK-based Avillion is partnering with pharmaceutical and biotechnology companies to co-develop and finance late stage therapeutics.

The company will use its clinical development and regulatory expertise to get the global approvals for a broad range of drugs and biologics. 

Lewis Cameron, CEO of Avillion said, “Avillion offers pharma and biotech companies compelling option to collaborate late stage drug approval projects globally. “ Mr. Cameron also said, “We have an experienced team focused on global drug development and approval, with the capability to optimize CRO management.”  

The management team is led by Lewis Cameron who has held senior positions in CRO companies including Chiltern International, Clearstone and LabCorp, Dr Allison Jeynes-Ellis has more than 20 years’ experience running clinical trials for pharmaceutical companies like BMS and Wyeth.

It has also been extensively involved in health technology appraisals across various countries.  Graham Higson (VP, Regulatory) has three decades of regulatory experience, including 5 years as the global head of regulatory affairs at AstraZeneca.  Abingworth  is a global investment group dedicated mainly to the life sciences and healthcare sector.

The company invests at all stages of development including early and late-stage venture financing, growth equity and public companies.  

Clarus Ventures is a life sciences venture capital company founded by a team of accomplished investment and operating professionals. 


Featured Articles

Global Population Health Summit took place in New York

Bone problems, cancer, anxiety, depression, self harm & suicide are among many problems that encounter individuals of transgender, experts say

MEDSIR research closer to ‘the end of chemotherapy’

Javier Cortés, of the International Breast Cancer Center, says results from MEDSIR’s PHERGain trial offer "an improvement in quality of life" for patients

5 minutes with Sonia Powar, BGF’s Healthcare Investments

Sonia Powar, BGF’s Head of Healthcare Investments in London, shares what she looks for in a multi-site healthcare business: Resilience, talent & expertise

The power of video technology in hospitals

Technology & AI

The future of healthcare: new technologies, IoT & more

Technology & AI

Ben Chodor of CareTalk Health & Notified explores telehealth

Telehealth & COVID-19